Genes differentially expressed in prostate cancer

BJU International

Volumn 93, Issue 8, 2004, Pages 1151-1155

  Eder, I E ^a   Bektic, J ^a   Haag, P ^a   Bartsch, G ^a   Klocker, H ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; CLUSTERIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR BETA; FATTY ACID SYNTHASE; GERANYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; MYC PROTEIN; PROTEIN BCL 2; SOMATOMEDIN BINDING PROTEIN;

ANALYTICAL PARAMETERS; CARCINOGENESIS; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION; GENETIC PROCEDURES; GENETIC REGULATION; GENETIC TRANSDUCTION; HUMAN; METASTASIS; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; TUMOR SUPPRESSOR GENE; UPREGULATION;

DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 2942580629     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04869.x     Document Type: Review

References (54)

1. Horninger W, Reissigl A, Rogatsch H et al. Prostate cancer screening in the Tyrol, Austria. Experience and results. Eur J Cancer 2000; 36: 1322-35
2. Eder IE, Culig Z, Putz T, Nessler-Menardi C, Bartsch G, Klocker H. Molecular biology of the androgen receptor: From molecular understanding to the clinic. Eur Urol 2001; 40: 241-51
3. Meehan KL, Holland JW, Dawkins HJ. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 2002; 50: 54-63
4. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Med 1998; 4: 844-7
5. Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent JM. Expression profiling using cDNA microarrays. Nature Genet 1999; 21 (Suppl.): 10-4
6. Chi KN, Gleave ME, Klasa R et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 3920-7
7. Bubendorf L, Komer M, Kononen J et al. Hormone therapy failure in human prostate cancer. Analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 1999; 91: 1758-64
8. Kiyama S, Morrison K, Zellweger T et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003; 63: 3575-84
9. Eder IE, Haag P, Basik M et al. Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells. Mol Carcinogen 2003; 37: 181-91
10. Nahta R, Hortobagyi GN, Esteva FJ. Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist 2003; 8: 5-17
11. Jorda M, Morales A, Ghorab Z, Fernandez G, Nadji M, Block N. Her2 expression in prostatic cancer: a comparison with mammary carcinoma. J Urol 2002; 168: 1412-4
12. Mellinghoff IK, Tran C, Sawyers CL. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res 2002; 62: 5254-9
13. Lau KM, Tam NN, Thompson C, Cheng RY, Leung YK, Ho SM. Age-associated changes in histology and gene-expression profile in the rat ventral prostate. Lab Invest 2003; 83: 743-57
14. Xu LL, Su YP, Labiche R et al. Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int J Cancer 2001; 92: 322-8
15. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000; 60: 170-6
16. Gleave ME, Miyake H, Zellweger T et al. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message-2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology 2001; 58 (Suppl. 2A): 39-49
17. Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000; 6: 1655-63
18. Bussemakers MJ, van Bokhoven A, Verhaegh GW et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-9
19. Nelson PS, Clegg N, Arnold H et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002; 99: 11890-5
20. Jiang F, Yang L, Cai X, Cyriac J, Shechter I, Wang Z. Farnesyl diphosphate synthase is abundantly expressed and regulated by androgen in rat prostatic epithelial cells. J Steroid Biochim Mol Biol 2001; 78: 123-30
21. Swinnen JV, Roskams T, Joniau S et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 2002; 98: 19-22
22. Welsh JB, Sapinoso LM, Su AI et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001; 61: 5974-8
23. Swinnen JV, Van Veldhoven PP, Timmermans L et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 2003; 302: 898-903
24. Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, Singh G. Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res 2003; 63: 2306-11
25. Zheng J, Rudra-Ganguly N, Powell WC, Roy-Burman P. Suppression of prostate carcinoma cell invasion by expression of antisense L-plastin gene. Am J Pathol 1999; 155: 115-22
26. Chakravarti A, Zehr EM, Zietman AL et al. Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate patients with clinically localized prostate cancer-results from a pilot study. Urology 2000; 55: 635-8
27. Kanoh Y, Akahoshi T, Ohara T et al. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res 2002; 22: 1813-7
28. Wilson MJ, Sellers RG, Wiehr C, Melamud O, Pei D, Peehl DM. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. J Cell Physiol 2002; 191: 208-16
29. Untergasser G, Koch HB, Menssen A, Hermeking H. Characterization of epithelial senescence by serial analysis of gene expression: Identification of genes potentially involved in prostate cancer. Cancer Res 2002; 62: 6255-62
30. Baron V, De Gregorio G, Krones-Herzig A et al. Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo. Oncogene 2003; 22: 4194-204
31. Mousses S, Bubendorf L, Wagner U et al. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res 2002; 62: 1256-60
32. Fixemer T, Remberger K, Bonkhoff H. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 2003; 54: 79-87
33. Stamey TA, Warrington JA, Caldwell MC et al. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol 2001; 166: 2171-7
34. Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-9
35. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003; 95: 661-8
36. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997; 158: 131-7
37. Tsihlias J, Kapusta LR, DeBoer G et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998; 58: 542-8
38. Mashal RD, Lester S, Corless C et al. Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res 1996; 56: 4159-63
39. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-7
40. Wong AS, Gumbiner BM. Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J Cell Biol 2003; 161: 1191-203
41. Rubin MA, Mucci NR, Figurski J, Fecko A, Pienta KJ, Day ML. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol 2001; 32: 690-7
42. Gelmann EP, Bowen C, Bubendorf L. Expression of NKX3.1 in normal and malignant tissues. Prostate 2003; 55: 111-7
43. Kim MJ, Cardiff RD, Desai N et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 2002; 99: 2884-9
44. Brooks JD, Weinstein M, Lin X et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 1998; 7: 531-6
45. Miyata Y, Sakai H, Hayashi T, Kanetake H. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 2003; 54: 125-32
46. Stattin P, Stenman UH, Riboli E, Hallmans G, Kaaks R. Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection. J Clin Endocrinol Metab 2001; 86: 5745-8
47. Nelson PS, Plymate SR, Wang K et al. Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. Cancer Res 1998; 58: 232-6
48. Porkka KP, Visakorpi T. Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library assay. J Pathol 2001; 193: 73-9
49. Harden SV, Guo Z, Epstein JI, Sidransky D. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol 2003; 169: 1138-42
50. Hessels D, Klein Gunnewiek JM, van Oort I et al. DD3 (PCAS)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-15
51. Schiller JH. New directions for ZD1839 in the treatment of solid tumors. Semin Oncol 2003; 30 (Suppl. 1): 49-55
52. Small EJ, Bok R, Reese DM, Sudilovsky D, Frohlich M. Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin Oncol 2001; 28 (Suppl. 4): 71-6
53. Schwaab T, Lewis LD, Cole BF et al. Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu. J Immunother 2001; 24: 79-87
54. Barton J, Blackledge G, Wakeling A, Growth factors and their receptors: new targets for prostate cancer therapy. Urology 2001; 58 (Suppl. 1): 114-22